Changes of retinal oxygen saturation during treatment of diabetic macular edema with a pre-defined regimen of aflibercept: a prospective study

Somar M. Hasan 1 & Martin Hammer 1 & Daniel Meller 1

Received: 18 January 2021 / Revised: 22 May 2021 / Accepted: 7 July 2021 / Published online: 1 September 2021
© The Author(s) 2021

Abstract

Purpose To study the effect of anti-VEGF therapy for diabetic macular edema (DME) on retinal oxygen saturation (O2S) and its correlation with functional and anatomical changes of retinal tissue.

Methods An interventional prospective single group study. Included were 10 eyes of 10 patients with visually significant DME which received a fixed regimen of intravitreal aflibercept every 4 weeks for 5 months, followed by 3 injections every 8 weeks, and were controlled monthly. Visual acuity (VA), central retinal thickness (CRT), arterial (aO2S), venous (vO2S) and arteriovenous difference (AVdO2S) retinal oxygen saturation were noted monthly. Changes after 5th (V6) injection and on last follow-up (V12) were studied. Correlations of different parameters were analyzed.

Results The aO2S did not change whereas vO2S decreased (62.2 ± 9.4 pre-op to 57.2 ± 10.5 on V6, p = 0.03). This remained unchanged at 59.4 ± 13.2 on V12 (p = 0.2) and was accompanied by an increase of AVdO2S (40.8 ± 8.3 pre-op to 44.8 ± 10.6, p = 0.03 on V6) which was followed by a non-significant decrease to 41.8 ± 11.3 on V12 (p = 0.06). We found no correlation between BCVA and aO2S. However, mild correlation between BCVA and both vO2S and AVdO2S (r = −0.2 p = 0.035 and r = 0.185 p = 0.05 respectively) was found. No correlation was found between CRT and aO2S, vO2S, or AVdO2S.

Conclusions During DME treatment with fixed regimen of intravitreal aflibercept over 11 months, we observed a reduction of vO2S and increase of AVdO2S which correlated with BCVA but not CRT. This could be explained by increasing consumption of O2S in the central retina and, possibly, by re-perfusion process.

Keywords Diabetic retinopathy · Retinal oxygen saturation · Diabetic macular edema · Anti-VEGF therapy · Aflibercept

Introduction

Changes of retinal vessel oxygen saturation (O2S) are known in eyes with diabetic retinopathy (DR). Increased arterial
(aO$_2$S) and venous (vO$_2$S) retinal oxygen saturation levels and decreased extraction were measured with increasing severity of DR [1–3]. This could be explained by three mechanisms: (1) capillary nonperfusion and shunting, (2) thickening of capillary vessel walls, and (3) greater affinity of hemoglobin HbA1C for oxygen in diabetic patients [3, 4]. In eyes with capillary shunting, there is bypassing of blood flow of parts of capillary network resulting in non-perfusion and reduced tissue oxygenation. In addition, thickening of capillary walls results in a higher diffusion barrier for oxygen between vessel lumen and tissue [3]. The presence of diabetic macular edema (DME) correlated with more pronounced increase of venous retinal oxygen saturation and decreased extraction compared with the DR without DME [2, 4] and might be explained by reduced retinal autoregulation by increasing severity of diabetic retinopathy [5]. However, a secondary effect of lower oxygen consumption of the central retina as a result of reduced function of the retinal cells cannot be excluded.

The first-line therapy of fovea involving DME is intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors and is known to improve visual acuity and reduce central retinal thickness (CRT). However, it is not known if improvement of visual acuity and reduction of DME correlate with changes of retinal O$_2$S. Such correlation might offer new insights which help in understanding the pathophysiology of the disease and its reaction on the anti-VEGF therapy. Treatment of vision threatening DME with 3 monthly injections of intravitreal ranibizumab followed by pro re nata administration did not show significant changes of retinal O$_2$S levels in spite of achieving improvement of visual acuity and reduction of macular edema [6]. Similar results were found after 3 monthly injections of intravitreal aflibercept [7]. On the other hand, studies reporting 12-month outcomes of treatment with ranibizumab or aflibercept showed that improvement of central retinal thickness can progress till month 12 accompanied with improvement of visual acuity [8, 9]. The aim of this study was to investigate the progression of retinal O$_2$S during a 12-month treatment period of visually significant DME with intravitreal aflibercept using a fixed treatment regimen and to study its correlation with functional (best corrected visual acuity—BCVA) and anatomical (CRT) parameters.

**Methods**

This is an interventional prospective single-group non-randomized, non-controlled study. We included patients with non-proliferative diabetic retinopathy and diabetic macular edema involving the fovea and resulting in vision loss. Inclusion and exclusion criteria are listed in Table 1. All patients received a recommended fixed regimen of five intravitreal injections of aflibercept 2 mg/0.05 ml (Eylea, Bayer Vital AG, Leverkusen, Germany) every 4 weeks followed by three injections every 8 weeks. Patients were followed monthly according to the pre-defined protocol as shown in Table 2. Before starting treatment, every patient underwent a thorough ocular examination including BCVA determined by ETDRS standards, Goldmann applanation intraocular tonometry, and slitlamp bio-microscopy for the anterior and posterior segment in mydriasis including staging of the DR using ETDRS grading system. O$_2$S was measured and CRT was documented using optical coherence tomography (OCT). All patients underwent fundus fluorescence angiography (FA). These examinations (except for FA) were repeated monthly after the first injection for 11 months.

**Measurement of oxygen saturation**

The pupil was dilated with tropicamide 5.0 mg/mL (Mydrum eye drops; Bausch + Lomb, Berlin, Germany) as the five photos of the retina were taken with the retinal vascular oximeter (IMEDOS Systems UG, Jena, Germany), focusing on the optic nerve head and the parapapillary vessels with intervals of approximately 30 s between them. Arteries and veins were marked by the same experienced examiner (SMH); and O2S in the arteries, veins, and the arteriovenous difference (AV-D) were automatically measured and averaged over a circumpapillary ring with an inner and outer diameter of 2 and 3 disk radii, respectively. The software VesselMap 3.60, a component of the oximeter, was also used. Optical densities of the vessels were measured as the logarithmic ratio of the fundus reflection at the vessel and besides the vessel. To exclude specular reflex from the vessel, pixels with a reflection above 20% over the mean value were excluded. The ratio of the optical densities at 610 nm to that at the isosbestic wavelength of 548 nm is proportional to the vessel hemoglobin oxygen saturation after compensation for vessel diameter and fundus pigmentation. A linear relationship between the optical density ratio and the relative oxygen saturation measurement was established by calibration. Vessel tracking and calculation of the oxygen saturation were done automatically by the software of the device. The reproducibility of the measurement was shown to be 2.5% in arteries and 3.25% in veins (mean standard deviation of repeated measurements) [10]. Examination was performed in a dark room without any illumination source other than the retinal oximeter.

**Optical coherence tomography**

As the pupil was still dilated following O2S measurement, OCT examination of the central retina (Cirrus HD-OCT 5000 Carl-Zeiss Meditec, Oberkochen, Germany) with use of the central macular cube settings and help of eye-tracker was performed. Examined central retina was divided using the ETDRS grid and thickness of the central (1 mm) ring was
documented. Included were only images with a quality of 5/10 or better.

The study was performed in accordance with the Declaration of Helsinki, and a signed informed consent was obtained from all participants before any study related examination was performed. The study protocol was approved by the ethical commission of the Jena university hospital, Germany.

Patients

The study enrolled 11 eyes of 11 patients with type-2 diabetes and non-proliferative diabetic retinopathy with diabetic macular edema and foveal involvement resulting in reduced visual acuity. One patient was lost from follow-up after the sixth visit because of hospitalization as a complication of her diabetes so that 10 eyes of 10 patients were available at the last visit for statistical analysis. No patient received anti-VEGF therapy to the other eye during study time.

BCVA, CRT, intraocular pressure, and vascular retinal O₂S were compared on three time points:

- Before starting treatment (visit 0)
- 4 weeks after the 5th injection corresponding to month 5 (visit 6), where the maximum effect of aflibercept is expected (4 weeks after the 5th injection performed every 4 weeks)

### Table 1

| Inclusion criteria | Exclusion criteria |
|--------------------|--------------------|
| Patients with non-treated diabetic macular edema | Proliferative DR or non-proliferative DR requiring or expected to need laser photocoagulation during the study period. |
| Able to sign a written informed consent | Any previous ocular surgical intervention other than non-complicated cataract surgery (this should have been performed 8 weeks before inclusion) |
| Age between 21 and 80 years | Any retinal pathology other than DR (vascular occlusion, hereditary retinal dystrophies, vitreomacular traction, etc.) |
| Able to complete the study protocol | Any macular pathology other than DME (any form or stage of macular degeneration, macular hole, macular edema of other reason than DME, etc.) |
| Best corrected visual acuity between 20/400 and 20/25 in the study eye | Spherical equivalent of more than +6.0 Diopters or less than −3.0 Diopters |
| Manufacturer’s criteria for aflibercept treatment | Systemic diseases which might affect retinal O₂S (COPD, renal insufficiency, etc.) |
| | Hypertension with hypertensive retinopathy ≥ II° |
| | History of stroke, transient ischemic attack or myocardial infarction |
| | Status post intravitreal injections |
| | Media opacities affecting fundus examination |
| | Any acute infection of the eye |
| | Advanced glaucoma with a cup to disk excavation ≥0.8 |
| | Pregnancy or lactation |

Abbreviations: DR diabetic retinopathy

### Table 2

| V 0  | V 1  | V 2  | V 3  | V 4  | V 5  | V 6  | V 7  | V 8  | V 9  | V 10 | V 11 | V 12 |
|------|------|------|------|------|------|------|------|------|------|------|------|------|
| IVIA | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    |     |     |
| Visus| X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    |
| IOP  | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    |
| Slitlamp | X | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    |
| O₂S  | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    |
| OCT  | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    |

Abbreviations: IVIA intravitreal injection of aflibercept, IOP intraocular pressure, O₂S retinal oxygen saturation, OCT optical coherence tomography
- 4 weeks after the 8th injection corresponding to month 11 (visit 12), where we wanted to measure the effect of a maintenance dose of 3 injections every 8 weeks.

Changes of every visit to the visit before were calculated for each of the different parameters (BCVA, CRT, aO2S, vO2S, and arteriovenous difference oxygen saturation (AVdO2S)) through all monthly visits. Correlations of these changes were studied.

**Statistical analysis**

The statistical analysis was performed using IBM SPSS Statistics Version 22.0 (IBM Corp., Armonk, NY, USA). All parameters were tested for normal distribution (Shapiro-Wilk test). In normally distributed data, the paired sample t-test and Pearson’s correlation test were used. Otherwise, Wilcoxon signed-rank and the Spearman correlation tests were used. All results are presented as mean ± standard deviation. A p value of ≤0.05 was considered significant.

**Results**

The basic data of all ten patients before starting therapy are listed in Table 3.

**Changes of BCVA, CRT, IOP, and DR**

Changes of these parameters on every visit are listed in Table 4. The BCVA improved on visit 6 from 64.2 ± 10.3 pre-op to 69.8 ± 10.2 ETDRS letters (p = 0.05) and remained stable on visit 12 at 71.0 ± 9.3 ETDRS letters (p > 0.05). The CRT reduced from 394 ± 73.9 μm pre-op to 308 ± 73.7 on visit 6 (p = 0.009) and continued to improve till visit 12 (290.1 ± 64.7 μm, p = 0.04). IOP remained stable at 17.1 ± 3.1, 17.2 ± 2.0, and 17.6 ± 2.9 mmHg pre-op, on visit 6 and on visit 12 (p = 0.9 and 0.7 respectively). No changes of the stage of DR were observed on visit 12.

**Changes of the retinal O2S**

The aO2S remained unchanged (pre-op 103.0 ± 7.1 to 102.0 ± 7.3 on visit 6 and to 101.2 ± 7.6 on visit 12, p = 0.39 and 0.74 respectively), although showing a downward trend. We observed a significant reduction of vO2S from 62.2 ± 9.4 pre-op to 57.2 ± 10.5 on visit 6 (p = 0.03) which then remained unchanged at 59.4 ± 13.2 on visit 12 (p = 0.2). This was accompanied by an increase of AVdO2S saturation from 40.8 ± 8.3 pre-op to 44.8 ± 10.6 (p = 0.03) on visit 6 and followed by a non-significant decrease to 41.8 ± 11.3 on last visit (p = 0.06) (Fig. 1).

Studying the correlations of changes between the different parameters (change of every visit to the visit before) showed a significant correlation of BCVA with CRT (r = −0.32, p > 0.001, Pearson correlation test). We found no correlation between BCVA and the aO2S (p > 0.05). However, we found a mild but significant correlation between the BCVA and both the vO2S and the AVdO2S (r = −0.2, p = 0.035 and r = 0.185, p = 0.05 respectively). No correlation was found between the CRT and the aO2S, vO2S, or AVdO2S.

| Patient | Sex | Age | Loc | IOP | Stage | CRT | BCVA | aO2S | vO2S | AVdO2S |
|---------|-----|-----|-----|-----|-------|-----|------|------|------|--------|
| 1       | F   | 62  | L   | 16  | Moderate | 320 | 79   | 100.91| 65.28 | 35.62  |
| 2       | M   | 66  | R   | 20  | Mild   | 343 | 72   | 100.56| 63.61 | 36.95  |
| 3       | F   | 81  | L   | 17  | Mild   | 463 | 56   | 92.98 | 45.40 | 47.58  |
| 4       | F   | 65  | L   | 22  | Severe | 498 | 54   | 100.69| 70.16 | 30.53  |
| 5       | M   | 77  | L   | 14  | Moderate| 270 | 55   | 108.92| 69.09 | 39.82  |
| 6       | M   | 41  | R   | 21  | Mild   | 384 | 75   | 96.34 | 55.97 | 40.37  |
| 7       | F   | 60  | R   | 18  | Mild   | 390 | 65   | 95.60 | 58.66 | 36.93  |
| 8       | M   | 60  | R   | 14  | Severe | 494 | 75   | 112.63| 58.42 | 54.21  |
| 9       | M   | 72  | L   | 13  | Severe | 395 | 60   | 111.62| 79.35 | 32.27  |
| 10      | M   | 50  | L   | 16  | Moderate| 383 | 51   | 109.62| 55.98 | 53.63  |
| Mean ± STD | 63.4±11.9 | 17.1 | N/A | 394±73.99 | 64.2±10.3 | 102.99±7.15 | 62.19±9.44 | 40.79±8.34 |

Abbreviations: LOC localization, L left, R right, IOP intraocular pressure in mmHg, Stage stage of diabetic retinopathy, CRT central retinal thickness in μm, BCVA best corrected visual acuity in ETDRS letters, aO2S arterial retinal oxygen saturation, vO2S venous retinal oxygen saturation, AVdO2S arteriovenous difference of retinal oxygen saturation.
Different pathologic features are associated with DR including apoptosis of vascular endothelial cells and pericytes, thickening of basement membrane, capillary occlusion, and breakdown of the blood-retinal barrier (BRB) [11]. Synthesis of VEGF is upregulated by different mechanisms including tissue hypoxia [12], and its concentrations in diabetic patients are 5 times that of age-matched controls [13]. Treatment of visually significant DME with anti-VEGF is now a standard of care and leads to improvement of VA and reduction of CRT. The effect of anti-VEGF therapy on the retinal oxygen saturation and its correlation with the functional and anatomical changes during therapy is not well studied. In our study, we report for the first time the changes of retinal O₂S during treatment of DME with a pre-defined treatment regimen over a 12-month period.

We observed an improvement of the visual acuity from 64.2 ± 10.34 letters pre-op to 69.5 ± 9.7 on visit 6 and to 71.0 ± 9.36 on the last visit. Similar results were found in other studies using aflibercept and giving a mean of 8 injections in 1 year [14]. In other studies, an even further improvement was achieved when using a different treatment protocol which allowed laser photocoagulation and more injections [9]. The central retinal thickness reduced from 394 ± 73.9 μm pre-op to 308 ± 73.7 after on visit 6 (p = 0.009) and continued to reduce till last visit to 290.1 ± 64.7 (−104 μm on month 12). This is also in accordance with published data [14].

Studying progress of retinal O₂S, we did not see significant changes of aO₂S during treatment course but we observed a significant reduction of vO₂S, a change of −8% which remained stable on last visit and was accompanied by an increase of AVdO₂S on visit 6 and remained stable on last visit. This contradicts results of other studies, where a- and vO₂S did not change during treatment with aflibercept or ranibizumab. These studies, however, had either a shorter

| Table 4  | Outcomes over 11 visits (mean ± standard deviation, p values are calculated for every visit compared to V0) |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Patient | BCVA | CRT | IOP | aO₂S | vO₂S | AVdO₂S |
| V0 | 64.2 ±10.3 | 394±73.9 | 17.1 ±3.1 | 103.0 ±7.1 | 62.2 ±9.4 | 40.8 ±8.3 |
| V1 | 69.2 ±9.0 | 316±66.5 | 15.2 ±3.0 | 102.2 ±8.3 | 62.0 ±11.1 | 41.1 ±8.4 |
| V2 | 68.8 ±7.94 | 306±60.0 | 15.7 ±3.5 | 104.8 ±7.4 | 64.6 ±9.6 | 40.2 ±6.6 |
| V3 | 68.5 ±9.16 | 304±70.3 | 15.9 ±4.7 | 103.8 ±8.2 | 62.9 ±11.2 | 44.7 ±11.4 |
| V4 | 66.8 ±10.38 | 302±69.39 | 16.5 ±3.3 | 103.5 ±8.4 | 62.9 ±11.2 | 40.6 ±11.2 |
| V5 | 69.5 ±7.90 | 301±73.21 | 16.7 ±2.7 | 102.0 ±8.1 | 62.5 ±11.0 | 44.8 ±10.6 |
| V6 | 69.8 ±10.22 | 302±68.07 | 16.7 ±2.4 | 102.0 ±7.0 | 57.2 ±10.5 | 41.0 ±10.6 |
| V7 | 69.5 ±9.70 | 301±66.9 | 16.7 ±2.7 | 102.0 ±7.0 | 62.0 ±9.7 | 43.0 ±10.8 |
| V8 | 69.2 ±8.99 | 302±69.99 | 16.7 ±2.4 | 102.0 ±7.0 | 62.0 ±9.7 | 39.1 ±9.1 |
| V9 | 69.2 ±8.99 | 301±66.9 | 16.7 ±2.4 | 102.0 ±7.0 | 62.0 ±9.7 | 39.1 ±9.1 |
| V10 | 69.2 ±8.99 | 301±66.9 | 16.7 ±2.4 | 102.0 ±7.0 | 62.0 ±9.7 | 39.1 ±9.1 |
| V11 | 69.2 ±8.99 | 301±66.9 | 16.7 ±2.4 | 102.0 ±7.0 | 62.0 ±9.7 | 39.1 ±9.1 |
| V12 | 69.2 ±8.99 | 301±66.9 | 16.7 ±2.4 | 102.0 ±7.0 | 62.0 ±9.7 | 39.1 ±9.1 |

Abbreviations: V: visit, BCVA: best corrected visual acuity in ETDRS letters, CRT: central retinal thickness in μm, IOP: intraocular pressure in mmHg

Fig. 1 Progression of retinal oxygen saturation on visit 0, visit 6, and visit 12. Graphic generated using IBM SPSS Statistics Version 22.0 (IBM Corp., Armonk, NY, USA). The * sign points to statistically significant difference

**Discussion**

Different pathologic features are associated with DR including apoptosis of vascular endothelial cells and pericytes, thickening of basement membrane, capillary occlusion, and breakdown of the blood-retinal barrier (BRB) [11]. Synthesis of VEGF is upregulated by different mechanisms including tissue hypoxia [12], and its concentrations in diabetic patients are 5 times that of age-matched controls [13]. Treatment of visually significant DME with anti-VEGF is now a standard of care and leads to improvement of VA and reduction of CRT. The effect of anti-VEGF therapy on the retinal oxygen saturation and its correlation with the functional and anatomical changes during therapy is not well studied. In our study, we report for the first time the changes of retinal O₂S during treatment of DME with a pre-defined treatment regimen over a 12-month period.

We observed an improvement of the visual acuity from 64.2 ± 10.34 letters pre-op to 69.5 ± 9.7 on visit 6 and to 71.0 ± 9.36 on the last visit. Similar results were found in other studies using aflibercept and giving a mean of 8 injections in 1 year [14]. In other studies, an even further improvement was achieved when using a different treatment protocol which allowed laser photocoagulation and more injections [9]. The central retinal thickness reduced from 394 ± 73.9 μm pre-op to 308 ± 73.7 after on visit 6 (p = 0.009) and continued to reduce till last visit to 290.1 ± 64.7 (−104 μm on month 12). This is also in accordance with published data [14].

Studying progress of retinal O₂S, we did not see significant changes of aO₂S during treatment course but we observed a significant reduction of vO₂S, a change of −8% which remained stable on last visit and was accompanied by an increase of AVdO₂S on visit 6 and remained stable on last visit. This contradicts results of other studies, where a- and vO₂S did not change during treatment with aflibercept or ranibizumab. These studies, however, had either a shorter
follow-up time of 3 months [7], which might not be sufficient in many cases to control the disease and reach the end results functionally or anatomically or used another treatment regimen like a loading dose of 3 injections followed by pro re nata schema and allowed laser photocoagulation after month 3, resulting in less injections (6.6 ± 2.5) in 1 year. However, a higher central retinal thickness was found after 6 months (346.2 ± 109.4 μm) compared to our study [6]. The effect of laser photocoagulation on retinal O2S is controversial. This is why patients who might need laser photocoagulation during the study time were excluded in our study [1, 15, 16].

The decrease of vO2S and increase of AVdO2S could be explained by different mechanisms. (1) Improvement of severity of DR following treatment with anti-VEGF with aflibercept associating with more improvement at year 1 and 2 even in the absence of re-perfusions might have played a role [17, 18], as less severe retinopathy is associated with lower vO2S and higher AVdO2S [1, 2]. In our study, we did not observe an improvement of the DR but we had 7 of 10 eyes (70%) with a mild to moderate disease where improvement might not be detected through the ETDRS scale. Eyes with active proliferative DR were excluded from study. (2) A re-perfusion process in areas of non-perfusion after treatment of DR with anti-VEGF [19] was reported, although this is controversial [18]. The reperfusion may result in increased consumption of O2 by the re-perfused retinal areas and reduction of the vO2S. These changes of vO2S were not accompanied with changes of aO2S but with an increased AVdO2S, which might point to the possibility of increasing oxygen consumption of the retinal tissue during treatment with aflibercept. In mice retinas suffering from oxygen-induced injury and developing hypoxia, Arias et al. reported a significant improvement of the function of amacrine cells measured with electoretinogram after treatment with aflibercept compared with non-treated mice [20]. These changes were accompanied with improvement of the a and b waves pointing to an improved retinal function. Improvement of inner retinal cells, especially amacrine cells, might have led to increased O2 consumption and might partly explain our results.

The vO2S correlated mildly but significantly with the visual acuity. This inverse correlation, where increased visual acuity was associated with lower vO2S levels, could also be explained by increasing O2 consumption as retinal cells restore their function achieving a better BCVA, independent of the central retinal thickness and the anatomical progression of the central retina. It is well known that oxygen consumption is higher in the parafoveal retina compared with the peripheral retina and it even increases in case of hypoxia which is a main component of the pathophysiology of DME [21]. As to our knowledge, our study is the first to report the correlations of the O2S with functional (BCVA) and anatomical (CRT) parameters and to show a significant correlation of the changing vO2S with the visual acuity.

Our study has some limitations: we had a small sample of 10 eyes and studies with larger samples are needed to verify our results. Wide field fluorescein angiography or OCT-angiography was not part of our study so that we were not able to evaluate the role of re-perfusion or quantitatively grade the severity of DR in our sample although the clinical grading system which we used showed no changes of the severity of DR during study period. Still, this system does not include assessment of peripheral ischemia and its possible contribution to the changes of O2S.

Conclusion

Our study is the first to report the effect of treatment of eyes with DME with fixed treatment regimen of intravitreal aflibercept on retinal vascular O2S over a 12-month period and to describe its correlation with BCVA and CRT. Reduction of vO2S and increase of AVdO2S over the study period and its correlation with BCVA but not CRT could be explained by increased consumption of O2 in the central retina and, possibly, by a re-perfusion process. Studies with larger sample size and inclusion of wide field angiography and observing changes of DR could offer a verification and additional explanation of our findings.

Data availability All collected data are available on demand.

Declarations

Conflict of interest The authors declare no competing interests.

Consent to participate The study was approved by the ethical commission of the Jena university hospital, Germany.

Consent for publication Consent to publish data was obtained from all patients.

Funding Open access funding enabled and organized by Projekt DEAL. This was an investigator-initiated study which received a financial support from Bayer Vital GmbH, Leverkusen, Germany. This support did not affect the design, performance, or the results of the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Hammer M, Vilser W, Riemer T, Mandecka A, Schweitzer D, Kuhn U, Dawczynski J, Liestl F, Strobel J (2009) Diabetic patients with retinopathy show increased retinal venous oxygen saturation. Graefes Arch Clin Exp Ophthalmol 247:1025–1030. https://doi.org/10.1007/s00417-009-1078-6

2. Jorgensen CM, Hardarson SH, Bek T (2014) The oxygen saturation in retinal vessels from diabetic patients depends on the severity and type of vision-threatening retinopathy. Acta Ophthalmol 92:34–39. https://doi.org/10.1111/aos.12283

3. Hammer M, Vilser W, Riemer T, Mandecka A, Schweitzer D, Jorgensen CM, Hardarson SH, Bek T (2014) Oxygen saturation of retinal vessels in all stages of diabetic retinopathy and correlation to ultra-wide field fluorescein angiography. Invest Ophthalmol Vis Sci 57:5278–5284. https://doi.org/10.1094/IOVS.14-14811

4. Hardarson SH, Stefansson E (2012) Retinal oxygen saturation is altered in diabetic retinopathy. Br J Ophthalmol 96:560–563. https://doi.org/10.1136/bjophthalmol-2011-300640

5. Frederiksen CA, Jeppesen P, Knudsen ST, Poulsen PL, Mogensen CE, Bek T (2006) The blood pressure-induced diameter response of retinal arterioles decreases with increasing diabetic maculopathy. Graefes Arch Clin Exp Ophthalmol 244:1255–1261. https://doi.org/10.1007/s00417-006-0262-1

6. Takasago Y, Fujita Y, Nakano Y, Osuka R, Miyake M, Muraoka Y, Tsujikawa A (2019) Ranibizumab treatment improves diabetic macular oedema without influencing retinal oximetry parameters. Acta Ophthalmol 97:e1048–e1053. https://doi.org/10.1111/aos.14145

7. Blindbaek SL, Peto T, Grauslund J (2020) Correlation between diabetic retinopathy severity and oxygen metabolism in patients with diabetic macular edema during treatment with intravitreal aflibercept. Ophthalmic Res 63:106–113. https://doi.org/10.1159/000503930

8. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlimgemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A, group Rs (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118:615–625. https://doi.org/10.1016/j.ophtha.2011.01.031

9. Diabetic Retinopathy Clinical Research N, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193–1203. https://doi.org/10.1056/NEJMoa1414264

10. Hammer M, Vilser W, Riemer T, Schweitzer D (2008) Retinal vessel oxyimetry-calibration, compensation for vessel diameter and fundus pigmentation, and reproducibility. J Biomed Opt 13:054015. https://doi.org/10.1117/1.2976032

11. Stewart MW (2014) Anti-VEGF therapy for diabetic macular edema. Curr Diab Rep 14:510. https://doi.org/10.1007/s11892-014-0510-4

12. Orat Y, Porat R, Keshet E (2001) Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 280:C1367–C1374. https://doi.org/10.1152/ajpcell.2001.280.6.C1367

13. Funk M, Schmiderger G, Maar N, Bolz M, Benesch T, Zlabinger GJ, Schmidt-Erfurth UM (2010) Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina 30:1412–1419. https://doi.org/10.1097/IAE.0b013e3181e95c0

14. Bonnin S, Dupas B, Lavia C, Erginay A, Dhundass M, Couturier A, Au Yeung KH, Englmaier V, Merdausl M, Schaarschmidt M, Ader W, Kiss S (2017) Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections. Clin Ophthalmol 11:193–200. https://doi.org/10.2147/OPHTH.S118807

15. Rojo Arias JE, Economopoulou M, Juarez Lopez DA, Kurzbach A, Au Yeung KH, Englimaier V, Merdausl M, Schaarschmidt M, Ader W, Morawietz H, Funk RHW, Jasrai J (2020) VEGF-Trap is a potent modulator of vasoregenerative responses and protects dopaminergic amacrine network integrity in degenerative ischemic neovascular retinopathy. J Neurochem 153:390–412. https://doi.org/10.1111/jn.14875

16. Yu DY, Cringe SI, Su EN (2005) Intraretinal oxygen distribution in the monkey retina and the response to systemic hyperoxia. Invest Ophthalmol Vis Sci 46:4728–4733. https://doi.org/10.1167/iovs.05-0694

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.